Cary N. Robertson, MD, Associate Professor
Professor of Surgery
Office:
3007 Snyderman Bldg, 905 La Salle Street, Durham, NC 27710
Campus Mail:
DUMC DUMC Box 103868, Durham, NC 27710
Clinical research interests:
Clinical trials of novel diagnostic tests and therapies for genitourinary malignancies, with a strong focus on bladder cancer.
Basic science research interests:
Immune therapies for cancer, hyperthermia and heat-based treatment of cancer, molecular biology of genitourinary cancers, novel diagnostics and therapies for genitourinary cancers
Education and Training
- Fellowship, Urologic Oncology, Mayo Clinic, 2005 - 2008
- Residency, Urology, Universite Laval (Canada), 2001 - 2005
- M.S., Mayo Clinic, Alix School of Medicine, 2011
- M.D., University of Alberta (Canada), 2000
- B.S., University of Alberta (Canada), 1999
In the News
- I used to be a normal urinator. Then I reached my 50sJuly 3, 2021
- Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortageApril 1, 2021
- Intravesical hyperthermia with high-dose mitomycin-C shows promise as BCG alternative for NMIBCFebruary 23, 2021
- For those at risk for cancer, weighing the risk of covid-19 with delays in screening and treatmentJuly 19, 2020
- More than half of men over 60 may have problems in the bedroom. Our columnist confesses. April 10, 2020
- Why online reviews are not the best way to choose a doctorDecember 2, 2017
- The Basics Behind Bladder Cancer Treatment GainsOctober 5, 2017
- Scientists study whether hyperthermia treatment makes chemo more effectiveDecember 15, 2015
- Guys, here’s why it’s not worth testing yourself for a ‘lump’ down thereFebruary 16, 2015
- What's in a Name? New Rules for Doctor-Patient IntroductionsMarch 12, 2014
- Impotence more common in men who pop painkillersMarch 2, 2011
- HAL Does Not Improve Bladder Cancer SurvivalJune 18, 2009
- ED may herald coronary heart disease.August 1, 2007
Selected Grants
- Enfortumab vedotin treatment in non-muscle invasive bladder cancer Pro00108709
- A Phase 3 Study of CG0070 in Patients with Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus CalmetteGuerin (BCG)
- A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (M
- LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination with Anti-PD-1/L1 Checkpoint Inhibitors in Patients with Advanced Solid Tumors
- PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY BLADDER CANCER
- Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Altera
- Duke CTSA (TL1)
- Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancer
- Genomic Subtyping and Profiling T1/T2 UC of Bladder - Pro00106608
- Translational Research in Surgical Oncology
- A PHASE Ib/II, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OR WITHOUT BACILLE CALMETTE-GUÉRIN IN PATIENTS WITH HIGH-RISK NON¿MUSCLEINVASIVE BLADDER CANCER
- A Canine Model for Human High-Risk Non-Muscle Invasive Human Bladder Cancer-Molecular and Environmental Considerations
- A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder C
- The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma
A Multicenter, Prospective Blinded Pivotal Study - Heat Targeted Therapy for Bladder Cancer
- TAR-200 Study
- Synergistic Immuno-Photo-Nanotherapy for Bladder Cancer
- Therapeutic targeting of B7-H3 to reverse prostate cancer treatment resistance.
- BMS Bladder and Prostate Practicum 2019
- Evaluation of the UroVysion Test in Predicting Recurrence and/or Progression of Disease in Patients Receiving initial BCG for Primary High Grade Ta-T1 and CIS Urothelial Carcinoma of the Bladder
- A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel on Ablation of Upper Urinary Tract Urothelial Carcinoma
- Pig Bladder Hyperthermia Testing Device
- Bladder Tumor TURBT Study
- Phase II Trial of Aerobic Training in Metastatic Breast Cancer
- Randomized Trial of Optimal Type of Aerobic Training in Breast Cancer